HERNEXEOS (zongertinib)

TherapyBoehringer Ingelheim

HERNEXEOS (zongertinib) by Boehringer Ingelheim is a targeted therapy used in select biomarker-defined lung cancers.

Approvals

Indications

Biomarkers

Mapped tests

Where this therapy is approved with a companion diagnostic

Each row represents a defined combination of indication, biomarker criteria, and HERNEXEOS. Select a testing pathway to see the eligible companion diagnostic tests.

Indication-specific approvals

Approvals where HERNEXEOS is tied to a specific indication and biomarker definition.

Indication	Biomarker criteria	Notes
Non-Small Cell Lung Cancer (NSCLC) Solid Tumor · Lung	ERBB2 (HER2) Activating mutations in the tyrosine kinase domain (SNVs in exons 18-21 and exon 20 insertions)		View testing pathway →

Tumor-agnostic approvals

Approvals defined at the solid tumor level where biomarker criteria determine eligibility for HERNEXEOS.

No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.

Tests used in these approvals

These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering HERNEXEOS for eligible patients.

Test

Oncomine Dx Target Test

Life Technologies Corporation (ThermoFisher Scientific)

Method

NGS

Specimen

Tissue (FFPE)

1 approvalView test profile →

This view is scoped to HERNEXEOS (zongertinib). You can also see how it compares with other therapies and indications on the main Know Your Companions™ map.